Biologic & Biosimilar RA Drugs Industry Poised for Rapid Expansion, Projected to Hit $19.08 Billion by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Biologic & Biosimilar RA Drugs Market Heading Into 2029?
The market size for biologic and biosimilar RA drugs has seen a consistent increase recently. It is estimated to rise from $13.99 billion in 2024 to $14.57 billion in 2025, with a compound annual growth rate (CAGR) of 4.1%. Factors contributing to growth in the historic period include market adoption rates, results of clinical trials, changes in market share, outcomes of long-term patient treatment, and pricing strategies.
The market size for biologic & biosimilar RA drugs is predicted to experience robust expansion in the coming years, increasing to “$19.08 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%.” Factors contributing to this projected growth in the forecast period include the escalation in biologic drug creation, competitive dynamics, healthcare policies, patient predilections, and clinical research & advances. The forecast period is also expected to see emerging trends such as increased competition in the biosimilar market, personalized medicine and precision therapy, advancements in drug delivery solutions, emphasis on safety and effectiveness, and patient-focused healthcare.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp
Which Factors Are Pushing The Biologic & Biosimilar RA Drugs Market Forward?
The biologics and biosimilar RA drugs market is being propelled by the growth in the aging population and the escalating prevalence of rheumatoid arthritis. The term aging population pertains to individuals who are 60 years old or above. An autoimmune disorder, rheumatoid arthritis, occurs when a person’s immune system assails its own healthy cells, impacting the individual’s joints. The likelihood of rheumatoid arthritis heightens in older people, as the immune system weakens as one gets older. Compared to traditional drugs, biologics and biosimilar RA drugs serve as effective treatment options for rheumatoid arthritis. As reported by the World Health Organization (WHO), a specialized health entity of the United Nations situated in Switzerland, approximately 1 billion individuals aged 60 and above were present globally in 2020, a figure anticipated to surge to 1.4 billion by 2030, and 2.1 billion by 2050. Moreover, the Centers for Disease Control and Prevention, a governmental public health agency based in the US, predicts that by 2040, around 78.4 million adults in the USA will be afflicted with arthritis, while about 34.6 million people might experience limitations in activities due to arthritis. Therefore, the expansion in the number of elderly individuals combined with the rise in RA instances is enhancing the progress of the biologics and biosimilars RA drugs market.
Which Segment Held The Largest Share In The Biologic & Biosimilar RA Drugs Market In 2025?
The biologic & biosimilar ra drugs market covered in this report is segmented –
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches
What Future Market Trends Are Projected For The Biologic & Biosimilar RA Drugs Industry?
The advancement of new innovations holds significance as a majority trend in the biologic & biosimilar RA drugs market. The focus of major corporations in this market is on creating biosimilar therapies such as Dual Concentration Biosimilar Options as cost-effective substitutes. To illustrate, in July 2023, Organon, a healthcare firm based in the US, along with Samsung Bioepis from South Korea, introduced a biosimilar treatment, HADLIMA, a version of Humira (adalimumab), in the United States. The dual concentration biosimilar, delivering both high and low concentrations, endeavors to increase accessibility and affordability for autoimmune patients. Being priced 85% lower than Humira enhances patient reach. Further affirmed by the Arthritis Foundation, HADLIMA brings with it an autoinjector and a patient assistance program named HADLIMA For You, providing educational support and co-pay assistance. It is prescribed for diverse conditions, including rheumatoid arthritis and Crohn’s disease. Patients can access HADLIMA in citrate-free high concentration (100 mg/mL) and citrate-inclusive low concentration (50 mg/mL), ensuring uninterrupted patient care.
Which Organizations Are Driving Progress In The Biologic & Biosimilar RA Drugs Industry?
Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.
Get The Full Report Here:
Which Region Is Expected To Experience The Highest Growth In The Biologic & Biosimilar RA Drugs Industry?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
